Theradiag this week announced several management changes in line with the strategic organization of the company into two divisions following last year's acquisition of microRNA technology firm Prestizia.
Specifically, Philippe Lestage will lead Theradiag's In Vitro Diagnostics division while Valery Labonne will lead the company's Theranostics division.
Lestage joins Theradiag from Ortho Clinical Diagnostics, a Johnson & Johnson company, where he most recently held the position of marketing director of transfusion medicine for Europe. As head of the IVD business unit he will be responsible for commercial operations, marketing, and customer service for France and international markets.
Labonne is a former marketing director for Boehringer Ingelheim and co-founder of StarGen Consulting. As head of the Theranostics division he will oversee domestic and international sales and marketing, Theradiag said.
Meantime, Odile Prigneau, previously vice president of marketing and business development at Theradiag, is now general manager of Prestizia, the subsidiary of Theradiag dedicated to microRNAs. Prigneau will retain her business development responsibilities within Theradiag and assist Labonne's marketing staff members in transitioning to their new responsibilities.
Theradiag also said that Eric Sallen, current director of sales, is leaving the company this month.